至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

HNRNPA21 is upregulated in endocrine-resistant LCC9 breast cancer cells and alters the miRNA transcriptome when overexpressed in MCF-7 cells.

Sci Rep. 2019-07; 
KlingeCarolyn M,PiellKellianne M,TooleyChristine Schaner,RouchkaEr
Products/Services Used Details Operation
Molecular Biology Reagents MCF-7 cells were purchased from American Type Tissue Collection and were used within 9 passages from ATCC. MCF-7 cells were grown as described previously prior to transient transfection with pcDNA3.1+C-DYK or pcDNA3.1+C-DYK into which HNRNPA21 was cloned (purchased from GenScript, Piscataway, NJ, USA) Get A Quote

摘要

MicroRNAs are dysregulated in breast cancer. Heterogeneous Nuclear Ribonucleoprotein A21 (HNRNPA21) is a reader of the N(6)-methyladenosine (m6A) mark in primary-miRNAs (pri-miRNAs) and promotes DROSHA processing to precursor-miRNAs (pre-miRNAs). We examined the expression of writers, readers, and erasers of m6A and report that HNRNPA21 expression is higher in tamoxifen-resistant LCC9 breast cancer cells as compared to parental, tamoxifen-sensitive MCF-7 cells. To examine how increased expression of HNRNPA21 affects miRNA expression, HNRNPA21 was transiently overexpressed (~5.4-fold) in MCF-7 cells for whole genome miRNA profiling (miRNA-seq). 148 and 88 miRNAs were up- and down-regulated, respectivel... More

关键词